US stock · Healthcare sector · Medical Devices
Company Logo

Bruker Corporation

BRKRNASDAQ

68.79

USD
+0.35
(+0.51%)
Market Closed
38.22P/E
27Forward P/E
1.91P/E to S&P500
10.118BMarket CAP
0.28%Div Yield

Bruker Corporation

NASDAQ:BRKR

RECENT
PRICE

68.79

P/E
RATIO

38.22

(PEG:0.50)

P/E RATIO
RELATIVE
TO S&P

1.91

DIV
YLD

0.30%

High:
Low:

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

Legends

Stock price

1.21 Beta (1.0 Market)

0

0

0

0

0

0

0

0

0

-

% total return 11/22:

Stock

S&P

1y.

0

0

3y.

0

0

5y.

0

0

0

Percent shares traded:

0

0

0

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

TTM

Fiscal year

4.29

0.18

0.30

- -

5.28

0.30

0.12

- -

6.80

0.40

0.37

0.14

6.82

0.50

0.82

- -

7.94

0.58

0.76

0.00

9.99

0.56

0.20

- -

10.79

0.47

0.36

- -

11.05

0.48

0.57

- -

10.78

0.34

0.48

- -

9.65

0.60

1.16

- -

9.98

0.95

0.58

0.16

11.17

0.50

0.70

0.16

12.14

1.15

1.22

0.16

13.35

1.27

0.90

0.16

12.96

1.03

1.53

0.16

15.76

1.81

1.24

0.16

16.75

1.84

0.79

0.19

Revenue per share

Earnings per share

Free Cash Flow per sh

Dividends per share

0.08

1.89

0.16

2.49

0.29

1.92

0.10

2.55

0.19

3.19

0.33

3.76

0.44

4.26

0.30

5.08

0.20

4.56

0.20

4.32

0.23

4.25

0.28

4.59

0.31

5.74

0.47

5.84

0.63

6.27

0.60

7.07

0.82

6.72

CAPEX per share

Book Value per share

102

104

163

164

164

165

166

167

168

168

161

158

156

155

153

153

150

Comm.Shares outs.(m)

33.0

1.8

- -

30.0

1.7

- -

28.7

1.3

1.3%

16.5

0.2

- -

23.8

1.1

0.0%

29.9

1.8

- -

29.7

2.0

- -

37.9

2.2

- -

62.7

3.5

- -

32.6

1.6

- -

25.3

1.1

0.7%

56.0

2.4

0.6%

27.7

1.1

0.5%

33.5

1.4

0.4%

42.4

1.1

0.4%

40.4

1.3

0.2%

38.2

1.9

0.3%

Avg. annual P/E ratio

P/E relative to S&P500

Avg. annual div. yield

Capital Structure (30/9/22 | Q3)

Total liabilities
$2,389 m.

Total assets
$3,337 m.

Long-term debt
$1,137 m.

Cash and equiv.
$626 m.

Goodwill - -

Retained earnings $153 m.

Common stock 148 m. shares

Market Capitalisation
$10,118 m. (as of 26/11/22)

1,652

9.4%

1,791

8.7%

1,839

8.1%

1,809

5.8%

1,624

9.0%

1,611

11.0%

1,766

12.2%

1,896

13.8%

2,073

14.5%

1,988

12.5%

2,418

17.1%

2,506

16.9%

Revenue (m)

Operating margin

3

92

59

78

61

80

60

57

53

102

54

154

64

79

65

180

76

197

80

158

89

277

87

275

Depreciation (m)

Net profit (m)

35.4%

5.6%

43.5%

4.3%

34.3%

4.4%

41.2%

3.1%

18.0%

6.3%

13.0%

9.5%

59.4%

4.5%

26.0%

9.5%

29.4%

9.5%

28.5%

7.9%

28.7%

11.5%

32.7%

10.9%

Income tax rate

Net profit margin

438

219

622

628

336

707

783

354

846

784

354

766

677

266

726

751

392

686

834

416

725

705

323

897

1,151

813

907

1,133

842

961

1,533

1,222

1,085

1,172

1,137

948

Working capital (m)

Long-term debt (m)

Equity (m)

10.3%

8.9%

14.9%

7.3%

8.2%

11.0%

6.7%

6.9%

9.5%

5.1%

6.0%

7.4%

9.6%

8.0%

14.0%

12.9%

10.5%

22.4%

6.1%

10.9%

10.8%

12.5%

12.1%

20.0%

9.9%

10.7%

21.7%

7.5%

7.8%

16.4%

10.3%

10.7%

25.5%

11.2%

12.4%

29.0%

ROIC

Return on capital

Return on equity

Working Capital

2019

2020

2021

Cash assets

685

688

1,075

Receivables

362

335

417

Inventory

577

692

710

Other

172

166

177

Current assets

1,796

1,925

2,472

Acc. Payable

118

135

147

Debt due

21

24

112

Other

506

634

679

Current liab.

646

792

939

100.0%

(9.9)%

100.0%

(7.5)%

100.0%

(8.7)%

100.0%

(9.8)%

100.0%

40.6%

83.2%

186.0%

67.7%

142.4%

86.0%

8.2%

87.3%

111.4%

84.4%

61.5%

91.3%

89.5%

89.7%

291.6%

Plowback ratio

Div.&Repurch. to FCF

Bruker Corporation (US) started trading on August 5, 2000 (cik: 0001109354), operates in the Healthcare sector (Medical Devices industry), has 7,765 full-time employees, and is led by Dr. Frank Laukien. Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

Annual rates

(avg rate of change)

Past
5 y.

Past
10 y.

Revenues

8.56%

3.76%

Cash flow

23.55%

27.19%

Earnings

48.50%

27.74%

Dividends

-1.20%

- -

Book value

10.89%

5.43%

Insider trading

Type

Shares

Date

Kastner Marc A

Exempt

10,000

11/15/22

Kastner Marc A

Sale

10,000

11/15/22

Kastner Marc A

Exempt

10,000

11/15/22

Busse Falko

Award

4,719

08/11/22

Busse Falko

Award

4,658

08/11/22

Fiscal Year Ends

Quarterly Revenue (m)

Full fiscal year

I

II

III

IV

2020

424

425

511

628

1,988

2021

555

571

609

684

2,418

2022

595

588

639

- -

- -

Fiscal Year Ends

Earnings per share

Full fiscal year

I

II

III

IV

2020

0.07

0.16

0.35

0.45

1.03

2021

0.37

0.38

0.57

0.49

1.81

2022

0.41

0.33

0.60

- -

- -

Fiscal Year Ends

Quarterly dividends paid

Full fiscal year

I

II

III

IV

2020

0.04

0.04

0.04

0.04

0.16

2021

0.04

0.04

0.04

0.04

0.16

2022

0.05

0.05

0.05

- -

- -